On February 10, 2022 Lepu Biopharma of Beijing reported that it has begun taking orders for its $115 million Hong Kong IPO (Press release, Lepu Biopharma, FEB 10, 2022, View Source [SID1234608005]). The company has built a portfolio of oncology candidates that include eight products at clinical-stage, three in pre-clinical development and three combination therapies. It considers its PD-1 antibody a backbone of its development portfolio and has filed NDAs in China for two candidates. Because recent China life science IPOs have not held their value in post-IPO trading, the Lepu IPO will measure the appetite of investors for new biopharma offerings in 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!